GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)

This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in Germany. The study is designed as an umbrella study comprising several drug- and indication-specific modules. The present description covers Module A, which evaluates durvalumab used perioperatively in combination with FLOT chemotherapy (D-FLOT), followed by adjuvant durvalumab monotherapy in adults with resectable gastric or gastro-oesophageal junction adenocarcinoma in routine clinical practice in Germany.